

**18TH ANNUAL REPORT
2004-2005**



**NEOCURE
THERAPEUTICS LIMITED**



BOARD OF DIRECTORS

Sri.D.Krishna Kumar Raju	Chairman
Sri.D.Sreerama Raju	Managing Director
Sri. P.V.V.Prasad	Director
Sri.Ch.Srinivas	Director
Sri.P.Krupavaram	Director

BANKERS

The Karnataka Bank Limited
Manasa Bank Ltd
Bank of India

AUDITORS

M/s.P.Murali & Co.,
Chartered Accountants
6-3-655/2/3,
Somajiguda,
Hyderabad – 500 082
Phone: 23326666

REGISTERED OFFICE

G-4/B, SEIE,
Kattedan,
Hyderabad – 500 077.
Phone: 24361220
Fax: 24361220

SHARE TRANSFER AGENTS

M/s. AARTHI CONSULTANTS PRIVATE LIMITED
1-2-285, DOMALGUDA,
HYDERABAD – 500 029.
Phone: 27634445, 27638111, Fax: 27632184

NEOCURE THERAPEUTICS LIMITED



NOTICE

NOTICE is hereby given that the 18th Annual General Meeting of the members of M/s. NEOCURE THERAPEUTICS LIMITED will be held on Friday, the 30th day of September, 2005, at 10.00 A.M. at the Registered Office of the Company at G-4/B, SEIE, Kattedan, Hyderabad - 500 077 to consider the following Business:

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2005 and the Profit and Loss Account for the year ended as on that date and the Reports of the Directors and the Auditors thereon.
2. To appoint a Director in place of Sri D.Krishna Kumar Raju who retires by rotation and being eligible offers himself for reappointment.
3. To appoint Auditors and fix their remuneration.

SPECIAL BUSINESS:

4. To consider and if thought fit to pass with or without modification(s) the following resolution as Ordinary resolution.

"RESOLVED THAT pursuant to the provisions of Section 198,269,309,310,311 and read with Schedule XIII and other applicable provisions if any of the Companies Act 1956 as amended, consent of the company be and is hereby accorded for the appointment of Sri .D.SreeramaRaju as Managing Director for a period of 5 (Five Years) with effect from 1st October, 2004.

BY ORDER OF THE BOARD OF DIRECTORS
for NEOCURE THERAPEUTICS LIMITED

PLACE: HYDERABAD
DATE : 02-09-2005

(D.KRISHNA KUMAR RAJU)
CHAIRMAN

NOTES

- a) A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND THE PROXY NEED NOT BE A MEMBER.
- b) PROXIES TO BE EFFECTIVE MUST BE RECEIVED BY THE COMPANY NOT LATER THAN 48 HOURS BEFORE COMMENCEMENT OF THE MEETING.
- c) THE REGISTER OF MEMBERS AND SHARE TRANSFER BOOKS OF THE COMPANY WILL REMAIN CLOSED FROM 27-09-2005 to 30-09-2005 (BOTH DAYS INCLUSIVE)
- d) THE RELATIVE EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS SET OUT ABOVE, AS REQUIRED BY SEC.173 (2) OF THE COMPANIES ACT, 1956 IS ANNEXED HERETO.



**ANNEXURE TO THE NOTICE
EXPLANATORY STATEMENT**

Pursuant to Section 173(2) of the Companies Act, 1956.

ITEM NO:4

It is proposed to appoint Sri D.Srirama Raju as Managing Director of the company under the provisions of section 269 of the companies Act,1956. Sri D.Srirama Raju has agreed to act as the Managing Director of the company without any remuneration as the company is struggling to come out of the difficult period.

The Board recommends the resolution to shareholders for approval.

Except Sri D.Sreerama Raju and his son Sri.D.Krishna Kumar Raju, no other Director is directly or indirectly concerned or interested in the resolution.

**ADDITIONAL INFORMATION REQUIRED TO BE FURNISHED
UNDER THE LISTING AGREEMENT:**

As required under the Listing Agreement, the particulars of Directors who is proposed to be re-appointed are given below:

- 1. **Name** : **D.Krishna Kumar Raju**
- Age** : **49 Years**
- Qualifications** : **MBA (Hons)**
- Expertise** : **25 years vast experience in Pharmaceutical, Marketing, Management etc**
- Other Directorships** : **1**

Brief Profile of Sri.D.Sreerama Raju who was appointed as Managing Director.

- 1. **Name** : **D.SREERAMA RAJU**
- Age** : **69 Years**
- Qualifications** : **Graduate**
- Expertise** : **Vast Experience in Business Administration, Construction & Real Estate Business**
- Other Directorships** : **1**



DIRECTORS' REPORT

To
The Members of

M/s. NEOCURE THERAPEUTICS LIMITED

The Directors have pleasure in presenting the 18th Annual Report of the company together with the Audited Accounts for the year ended 31st March 2005.

OPERATIONS

Because of the stiff competition in the Pharmaceutical & Bio Technology business the Company has been continuously incurring losses and not able to sustain the competitive business. Hence, it is the need of the hour to search for good and financially strong parties to get good association and if necessary change in the line of activity and bring the company back into financially healthy organization.

FINANCIAL RESULTS

	Year Ended 31.03.2005 (Rs. in Lakhs)	Year Ended 31.03.2004 (Rs. in Lakhs)
Turnover	5.40	5.40
Profit (+) / Loss (-)	(66.97)	(47.67)
Balance Brought Forward	(1032.75)	(969.26)
Balance Carried Forward	(1123.63)	(1032.75)

MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

Pursuant to Clause 49 of the Listing Agreement, a Management Analysis Report is given below:

A. INDUSTRY BACKGROUND

The demand scenario for the pharmaceutical industry, in general, is good and ever increasing. Nevertheless, the industry is obsessed with stiff competition. In spite of the market competition, there is always a growing demand for this industry. Proper efforts are required to be made to fall in line with the changing trends and to achieve the targets and a better bottom line in the operations. Accordingly, plans are set to get good business partners and good associations to bring the company into healthy level.

B. INDUSTRY OUTLOOK

The need of the hour in the industry is to fall in line with the changing trends and to meet the lofty objectives. In general, the outlook for the industry can be categorized as excellent. The industry has to face the competitions and adopt itself to the use of latest technologies. There is also emergent need for helping the society by the use of latest bio technologies.

C. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The company has adequate internal control systems commensurate with the size of its operations and for the purpose of exercising adequate controls on the day-today operations. Systems are regularly reviewed to ensure effectiveness.

D. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES/INDUSTRIAL RELATIONS:

During the year there are no material developments in Human Resources as well as Industrial Relations.

ADDITIONAL INFORMATION AS REQUIRED U/S 217(1) (e) OF THE COMPANIES ACT, 1956

- (a) Conservation of Energy :The Company is monitoring the consumption of energy and is identifying measures for conservation of energy.
- (b) (i) Technology Absorption, adaptation and innovation:- No technology either indigenous or Foreign is involved.
- (ii) Research and Development (R & D): No research and Development has been carried out.
- (c) Foreign exchange earnings : NIL
Foreign exchange out go : NIL

NEOCURE THERAPEUTICS LIMITED



PARTICULARS OF EMPLOYEES

In pursuance of the provisions of section 217(2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975, the Directors are to report that no employee was in receipt of remuneration of Rs.24,00,000/- or more per annum or Rs.2,00,000/- or more per month where employed for a part of the year.

DIRECTORS

Sri.D.Sreerama Raju has been appointed as Managing Director of the company for a period of 5 years with effect from 1st October,2004 and his appointment has been placed in this notice for confirmation of the members in the Annual General Meeting.

Sri D.Krishna Kumar Raju retires by rotation at the ensuing Annual General Meeting and being eligible offers himself for re-appointment.

DIRECTORS' RESPONSIBILITY STATEMENT

- i) That in the preparation of the Annual Accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- ii) That the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Loss of the company for that period;
- iii) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv) The Directors had prepared the annual accounts on a going concern basis.

STATEMENT PURSUANT TO LISTING AGREEMENT

Presently the company's Equity shares are listed at Hyderabad Stock Exchange (HSE), Mumbai Stock Exchange (BSE) and National Stock Exchange (NSE). The Company has paid the Annual Listing Fee upto the year 2005-06 to NSE and 2002-03 for BSE&HSE.

CORPORATE GOVERNANCE

In order to bring more transparency in the conduct of business, the Stock Exchanges have amended the listing agreement incorporating the code of corporate governance to listed companies. Your Company has always been committed to the best practices in the governance of its affairs. Your company had taken steps and complied with most of the recommendations during the year. For the year under review, the Compliance Report is provided in the Corporate Governance section in this Report. The Auditors' Certificate on compliance with the mandatory requirements of Corporate Governance is given in "Annexure "A" to this Report.

PERSONNEL

The relations between the management and the staff were very cordial throughout this year. Your Directors take this opportunity to record their appreciation for the Co-Operation and loyal services rendered by the employees.

DEPOSITS

The company has not accepted any deposits during the year.

ACKNOWLEDGEMENTS

Your Directors gratefully acknowledge with thanks the constructive guidance and support extended by Banks and Government Agencies.

for and on behalf of the Board
for NEOCURE THERAPEUTICS LIMITED

PLACE : HYDERABAD.
DATE : 02-09-2005

(D.KRISHNA KUMAR RAJU)
CHAIRMAN

(D. SREERAMA RAJU)
MANAGING DIRECTOR

ANNEXURE – “A” TO DIRECTORS' REPORT- CORPORATE GOVERNANCE
(Pursuant to Clause 49 of the Listing Agreement)

1. Company’s Philosophy on code of governance:

The Basic philosophy of corporate governance of the company is to achieve business excellence and enhance shareholder value keeping in view the interests of all stake-holders. The company stands by transparency in all its dealings and strict regulatory compliance. The company believes that strong corporate governance is indispensable for healthy business growth and to be resilient in a vibrant capital market and is an important instrument of investor protection.

2. Board of Directors

a) Composition

The composition of Board of Directors of the company meets the stipulated requirements. The Board of Directors comprises of 1 Chairman, 1 Managing Director and 3 Independent Non Executive Directors. To be in line with the company's philosophy on Corporate Governance, all statutory subjects are placed before the Board to discharge its responsibilities as trustees of the Share Holders.

b) Attendance of each Director at the Board Meetings and the last AGM

Five Board Meetings were held during the year from April 01, 2004 to March 31, 2005 on the following dates:30.04.2004,29.07.2004,1.9.2004,29.10.2004 and 28.01.2005. The Last Annual General Meeting was held on 30th September, 2004. The attendance of each Director is as under:

Name of the Director	Category	No.of Other Directorships	No.of Committees in which member	No.of Board Meetings attended	Whether attended last AGM
Sri.D.Krishna Kumar Raju	Chairman	1	NIL	5	Yes
Sri.D.Sreerama Raju	Managing Director	1	NIL	5	Yes
Sri.P.V.V.Prasad	Independent Non-Executive	2	2	5	Yes
Sri.P.Krupavaram	Independent Non-Executive	NIL	2	5	Yes
Ch.Srinivas	Independent Non-Executive	1	2	5	Yes

3. AUDIT COMMITTEE:

During the year under review Four (4) meetings were held for approval of Un-audited Financial Results for each quarter ended.

NEOCURE THERAPEUTICS LIMITED



The constitution of the Committee and the attendance of each member of the Committee is given below:

Name of the Director	Designation	Wholetime/ Independent	Profession	Committee meetings attended
Sri.P.V.V.Prasad	Member	Independent	Business	4
Sri.Ch.Srinivas	Member	Independent	Business	4
Sri.P.Krupavaram	Member	Independent	Business	4

The meetings of Audit committee are also attended by the head of finance and Statutory Auditor as Invitees. The un-audited financial results for each quarter are approved by the audit committee before submission to the Board of Directors for approval and adoption.

Terms and reference of the Audit Committee include a review of;

- Financial reporting process
- Draft financial statements and auditor's report (before submission to the Board)
- Accounting policies and practices
- Internal controls and internal audit systems
- Risk management policies and practices
- Related party transactions
- Internal audit reports and adequacy of internal audit function

The role of the audit committee includes recommending the appointment and removal of the external auditor, discussion of the audit plan, fixation of audit fee and also approval of payment of fees for any other services.

4. Remuneration Committee

The Company does not have a "Remuneration Committee". Your Directors recommend that all such items that may be required to be discussed at a Meeting of the "Remuneration Committee" could be considered at a Meeting of the Board of Directors.

5. REMUNERATION OF DIRECTORS:

None of the Directors has drawn any remuneration or sitting fees during the financial year

6. Share Holders /Investors Grievance Committee:

The Committee oversees share transfers and monitors investor grievances. To look into the redressal of shareholders and investors complaints like – transfer of shares, non–receipt of balance Sheet, non-receipt of declared dividends etc.,

The Committee consists of the following Directors:

Sri.Ch.Srinivas	Member
Sri P.V.V.Prasad	Member
Sri.P.Krupavaram	Chairman

Sri.P.V.V.Prasad is the Compliance Officer.

The total No. of Complaints received and complied during the year were:15.

The Complaints had been attended to within seven days from the date of receipt of the complaint.

No complaints are outstanding as on 31st March, 2005



7. Details of Annual General Meetings: Location and time of the last Three AGMs.

AGM	YEAR	VENUE	DATE	TIME
17 TH	2003-2004	Registered Office	28-09-2004	10 A.M
16 TH	2002-2003	Registered Office	30-09-2003	3 P.M.
15 TH	2001-2002	Registered Office	30.09.2002	12 Noon

No Special resolution was put through postal ballot last year.

8. Disclosures

A. Disclosure on materially significant related party transactions i.e. transactions of the company of material nature with its promoters, the directors or the management's, their subsidiaries or relatives etc. that may have potential conflict with the interests of the company at large.

None

B. Details of non-compliance by the company, penalties, Strictures imposed on the company by stock Exchange or SEBI or any statutory authority, on any matter related to capital markets, during the last three years.

None

9. NOTES ON DIRECTORS APPOINTMENT/RE-APPOINTMENT:

Relevant details forms part of the explanatory statement to the notice of the Annual General Meeting/ Director's Report.

10. Means of Communications:

As per the listing requirements, the company publishes periodical financial results in leading English and regional newspapers for information. The Management Discussion and Analysis (MD& A) forms part of the annual report.

11. MANAGEMENT DISCUSSION AND ANALYSIS

Appended to this Report.

12. General Share Holder Information:

- a) AGM, Date, Time and Venue : 30th September, 2005 at 10 A.M.
at G-4/B, SEIE, Kattedan, Hyderabad -77
- b) Financial Calendar : April to March

Financial Reporting for:

Quarter ending June 30, 2005	Before end July 05
Quarter ending September 30, 2005	Before end October 05
Quarter ending December 31, 2005	Before end January 06
Quarter ending March 31, 2006	Before end April, 06
Annual General Meeting for FY ended 31 st March, 2006	Before end 30 th September, 2006

- c) Date of Book Closure : 24th September,2005 to 30th September, 2005 (both days inclusive)



- d) Dividend Payment date(s) : Not Applicable.
- e) Dividend Payment date(s) : Not Applicable.
- f) Listing on Stock Exchanges : Hyderabad, Mumbai and National Stock Exchange of India Limited. The Company has paid Annual listing Fee upto the year 2002-03 for the HSE&BSE and to NSE upto 2005-06.
- i) Stock Code**
 Hyderabad : Not Allotted
 Mumbai : 531624
 NSE : NEOCURTHER EQ.
- ii) Demat ISIN Number**
 NSDL – INE 695 B01017
 CDSL – INE 695 B01017
- g) Market Price Date: High : The Company was given Listing permission by
 Low during each : the Stock Exchange from
 Month in last Financial Year : Mumbai Stock Exchange 24-4-1996
 Hyderabad Stock Exchange 26-4-1996
 National Stock Exchange of India Limited 12-3-97

Month	Hyderabad Stock Exchange		Mumbai Stock Exchange		National Stock Exchange	
	High	Low	High (Rs.)	Low (Rs.)	High (Rs.)	Low (Rs.)
April, 2004	—	—	—	—	1.20	0.80
May, 2004	—	—	—	—	1.00	0.60
June, 2004	—	—	—	—	0.80	0.55
July, 2004	—	—	—	—	0.90	0.60
August, 2004	—	—	—	—	0.75	0.60
September, 2004	—	—	—	—	0.95	0.70
October, 2004	—	—	—	—	0.95	0.75
November, 2004	—	—	—	—	2.05	0.85
December, 2004	—	—	—	—	2.85	1.30
January, 2005	—	—	—	—	4.40	2.65
February, 2005	—	—	—	—	3.20	2.45
March, 2005	—	—	—	—	2.85	1.75

- h) Stock Performance in Comparison to Broad-based indices such as BSE Sensex, BZX 200, Nifty : The Share Price of the Company has been moving with the trend of the indices
- i) Registrars and Share Transfer Agent : Aarathi Consultants Private Limited
 1-2-285, Domalguda, Hyderabad-29.
 Phone : 27638111, 27634445
- j) Share Transfer System : The Share transfers are being effected physically by the Company's share transfer agents, M/s Aarathi Consultants Pvt. Ltd, Hyderabad.

NEOCURE THERAPEUTICS LIMITED



k) Distribution Shareholdings as on 31.3.2005

Share Holding of Nominal Value		Share Holders		Share Amount	
Rs.	Rs.	Numbers	% of Total	In Rs.	% of Total
(1)	(2)	(3)	(4)	(5)	(6)
Upto	5,000	4832	52.72	14066220.00	8.68
5,001	10,000	1638	17.87	14942820.00	9.22
10,001	20,000	1043	11.38	16870020.00	10.41
20,001	30,000	681	7.43	17629660.00	10.88
30,001	40,000	198	2.16	7335530.00	4.53
40,001	50,000	314	3.43	15026660.00	9.28
50,001	1,00,000	271	2.96	21123200.00	13.04
1,00,001	and above	188	2.05	54996890.00	33.95
TOTAL		9165	100.00	161991000.00	100.00

l) According to categories of shareholders as at 31st March 2005.

	CATEGORY	No. of Shares held	% age of shareholding
A	PROMOTER'S HOLDING:		
1.	Promoters*		
	- Indian Promoters	1153500	7.12
	- Foreign Promoters	30100	0.19
2.	Persons acting in Concert	-	-
B.	NON-PROMOTERS' HOLDING		
3.	Institutional Investors		
a.	Mutual Funds	-	-
b.	Banks, Financial Institutions, Insurance Companies (Central/ State Govt. Institutions / Non-government Institutions)	-	-
c.	FIs	-	-
4.	OTHERS		
a.	Private Corporate Bodies	1420359	8.77
b.	Indian Public	13063041	80.64
c.	NRIs / OCBs	532100	3.28
d.	Any other (please specify)		
TOTAL		16199100	100.00

- m) Dematerialisation of Shares and liquidity : The Company has entered into arrangements with both the depositories namely NSDL and CSDL for its shares dematerialization. The dematerialization status as on 31-3-05 is furnished hereunder.
NSDL:9372584 Shares; CDSL:1061581 shares
- n) Outstanding GDRs./ADRs./Warrants or any Convertible instruments conversion date and likely impact on equity. : The Company has not issued any GDRs. / ADRs. Warrants or any convertible instruments.
- o) Address for Correspondence : G-4/3, SEIE, Kattedan, Hyderabad - 500 077.

BY ORDER OF THE BOARD OF DIRECTORS
for NEOCURE THERAPEUTICS LIMITED

PLACE : HYDERABAD
DATE : 02-09-2005

(D.KRISHNA KUMAR RAJU)
CHAIRMAN

(D.SREERAMA RAJU)
MANAGING DIRECTOR

NEOCURE THERAPEUTICS LIMITED



Compliance Certificate on Corporate Governance

To
The Board of Directors of
Neocure Therapeutics Limited

We have read the report of the Board of Directors on Corporate Governance and have examined the relevant records relating to compliance condition of corporate governance of M/s. Neocure Therapeutics Limited ("the company") for the year ended 31st March, 2005 as stipulated in clause 49 of the listing agreement of the said company with the Stock Exchanges.

The compliance of the conditions of the Corporate Governance is the responsibility of the management. Our examination, conducted in the manner prescribed in the Guidance note on "Certification of Corporate Governance" issued by the Institute of Chartered Accountants of India was limited to procedures and implementation thereof adopted by the company for ensuring compliance with the conditions of Corporate Governance. Our examination was neither an audit nor was it conducted to express an opinion on the financial statements of the company.

In our opinion and to the best of our information and explanations given to us and on the basis of our examination described above, the company has complied with the conditions of Corporate Governance as stipulated in clause 49 the above mentioned Listing Agreement.

We further state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the management has conducted the affairs of the company.

For P.MURALI & CO.,
CHARTERED ACCOUNTANTS

PLACE : HYDERABAD
Date : 02-09-2005

P. MURALI MOHANA RAO
PARTNER

1,61,99,000
16,19,91,000

NEOCURE THERAPEUTICS LIMITED



AUDITORS' REPORT

To
The Members,
NEOCURE THERAPEUTICS LIMITED

We have audited the attached Balance Sheet of NEOCURE THERAPEUTICS LIMITED as at 31st March , 2005 and also the Profit & Loss Account for the period ended on the date annexed thereto and the cash flow statement for the period ended on that date. These financial statements are the responsibility of the Company's Management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statement. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall statement presentation. We believe that our audit provides a reasonable basis of our opinion .

As required by the Companies (Auditor's Report) order 2003 and as amended by the Companies (Auditor's Report) (Amendment) Order 2004, issued by the Central Government of India in terms of sub-section(4A) of section 227 of the Companies Act, 1956, we enclose in the annexure a statement on the matters specified in paragraphs 4 and 5 of the said order.

Further to our comments in the Annexure referred to above, we report that:

- (i) We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our Audit ;
- (ii) In our opinion, proper books of account as required by law have been kept by the company so far as appears from our examination of those books ;
- (iii) The Balance Sheet & Profit & Loss Account dealt with by this report are in agreement with the books of account ;
- (iv) In our opinion, the Balance Sheet & Profit & Loss Account dealt with by this report comply with the Accounting standards referred to in sub-section (3C) of Section 211 of Companies Act, 1956 ;
- (v) On the basis of written representations received from the Directors, as on 31st March , 2005 and taken on record by the Board of Directors, we report that none of the Directors is disqualified as on 31st March , 2005 from being appointed Director in terms of clause(g) of sub-section(1) of section 274 of the Companies Act, 1956;
- (vi) In our opinion and to the best of our information and according to the explanations given to us, the said accounts give the information required by the Companies Act, 1956, in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India ;
 - (a) In the case of the Balance Sheet, of the state of affairs of the Company as at 31st March , 2005;
 - (b) In the case of the Profit & Loss Account, of the Loss for the period ended on that date;

And

- (c) In the case of the Cash Flow, of the cash flows for the period ended on that date ;

For P.MURALI & CO.,
CHARTERED ACCOUNTANTS

P. MURALI MOHANA RAO
PARTNER

PLACE : HYDERABAD
Date : 02-09-2005

**ANNEXURE TO THE AUDITORS' REPORT**

- I. (a) The Company has maintained proper records showing full particulars including quantitative details and situation of Fixed Assets.
(b) As explained to us , the fixed assets have been physically verified by the management at reasonable intervals and no material discrepancies between the book records and the physical inventory have been noticed on such verification.
(c) The Company has not disposed off substantial part of the Fixed Assets during the year.
- II. (a) The Inventory has been physically verified during the year and in our opinion , the frequency of verification is reasonable.
(b) In our opinion, the procedures of the physical verification of inventory followed by the Management are reasonable and adequate in relation to the size of the Company and the nature of its business. The Company is maintaining proper records of inventory and as explained to us , no material discrepancies were noticed on physical verification of stocks as compared to book records.
- III. (a) The Company has not granted any loans, secured or unsecured to Companies, Firms or other Parties covered in the register maintained U/s.301 of the Companies Act, 1956.
(b) As the Company has not granted any loans ,the clause of whether the rate of interest & other terms and conditions on which loans have been granted to parties listed in the register maintained under section 301 is prejudicial to the interest of company, is not applicable.
(c) As no loans are granted by company, the clause of receipt of interest & principal amount from parties , is not applicable to the company.
(d) No loans have been granted to Companies,Firms & other parties listed in the register U/s.301 of the Companies Act, 1956 , hence overdue amount of more than rupees one lac does not arise and the clause is not applicable.
(e) The Company has not taken any loans, secured or unsecured from Companies, Firms or other Parties covered in the register maintained U/s.301 of the Companies Act, 1956.
(f) As the Company has not taken any loans ,the clause of whether the rate of interest & other terms and conditions on which loans have been taken from parties listed in the register maintained under section 301 is prejudicial to the interest of company, is not applicable.
(g) As no loans are taken by the company, the clause of repayment of interest & principal amount to parties , is not applicable to the company.
- IV. In our opinion and according to the information and explanations given to us, there are generally adequate internal control systems commensurate with the size of the company and the nature of its business with regard to purchase of inventory and fixed assets and for sale of goods and services. There is no continuing failure by the company to correct any major weaknesses in internal control.
- V. (a) In our opinion and according to the information and explanation given to us, since no contracts or arrangements referred to in section 301 of the Companies Act, 1956 have been made by the company in respect of any party in the financial year, the entry in the register U/s.301 of the Companies Act, 1956 does not arise.
(b) According to the information and explanations given to us, as no such contracts or arrangements made by the company , the applicability of the clause of charging the reasonable price having regard to the prevailing market prices at the relevant time does not arise.
- VI. The Company has not accepted any deposits from the public and hence the applicability of the clause of directives issued by the Reserve Bank of India and provisions of section 58A,58AA or any other relevant provisions of the Act and the rules framed there under does not arise. As per information and explanations given to us the order from the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal has not been received by the Company.



- VII. In our opinion, the company is having internal audit system, commensurate with its size and nature of its business.
- VIII. In respect of the Company, the Central Government has not prescribed maintenance of cost records under clause (d) of sub-section(1) of section 209 of the Companies Act, 1956.
- IX. a) The Company is regular in depositing statutory dues including PF,ESI, and any other statutory dues with the appropriate authorities and at the last of the financial year there were no amounts outstanding which were due for more than 6 months from the date they became payable.
b) According to the information and explanations given to us, no disputed amounts are payable in respect of PF,ESI, and any other statutory dues as at the end of the period, for a period more than six months from the date they became payable.
- X. The Company has been registered for a period of not less than 5 years, and its accumulated losses at the end of the financial year is more than fifty percent of its net worth and the company has not incurred cash losses in this financial year and in the immediately preceding financial year.
- XI. According to information and explanations given to us, the Company has defaulted in repayment of dues to financial Institutions or banks and the amount of default is as follows :
Karnataka Bank - Rs. 25,509,801
- XII. According to the information and explanations given to us, the Company has not granted any loans or advances on the basis of security by way of pledge of shares, debentures and other securities and hence the applicability of the clause regarding maintenance of adequate documents in respect of loans does not arise.
- XIII. This clause is not applicable to this Company as the Company is not covered by the provisions of special statute applicable to Chit Fund in respect of Nidhi/Mutual Benefit Fund/Societies.
- XIV. According to the information and explanations given to us, the company is not dealing or trading in shares, securities, Debentures and other investments and hence the provisions of clause 4(xiv) of the Companies (Auditor's Report) Order 2003, are not applicable to the Company.
- XV. According to the information and explanations given to us, the Company has not given any guarantee for loans taken by others from Banks or Financial Institutions, and hence the applicability of this clause regarding terms and conditions which are prejudicial to the interest of the company does not arise.
- XVI. According to the information and explanations given to us, the company has not obtained any Term Loans, hence this clause is not applicable.
- XVII. According to the information and explanations given to us, no funds are raised by the Company on short-term basis. Hence the clause of short term funds being used for long-term investment does not arise.
- XVIII. According to the information and explanations given to us, the Company has not made any preferential allotment of Shares to parties and Companies covered in the Register maintained under section 301 of the Companies Act, 1956 and hence the applicability of the clause regarding the price at which shares have been issued and whether the same is prejudicial to the interest of the Company does not arise.
- XIX. According to the information and explanations given to us, the company does not have any debentures and hence the applicability of the clause regarding the creation of security or charge in respect of debentures issued does not arise.
- XX. According to information and explanations given to us, the company has not raised money by way of public issues during the year, hence the clause regarding the disclosure by the management on the end use of money raised by Public Issue is not applicable.
- XXI. According to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the year under audit.

For **P.MURALI & CO.,**
CHARTERED ACCOUNTANTS

P. MURALI MOHANA RAO
PARTNER

PLACE : HYDERABAD
DATE : 02-09-2005

NEOCURE THERAPEUTICS LIMITED



BALANCE SHEET AS AT 31-03-2005

PARTICULARS	SCHEDULE No.	AS AT 31-03-2005 (Rupees)	AS AT 31-03-2004 (Rupees)
I SOURCES OF FUNDS			
1. SHAREHOLDERS' FUNDS			
a. Capital	1	161,991,000	161,991,000
b. Reserves & Surplus		37,113,500	37,113,500
2. LOAN FUNDS			
a. Secured Loans	2	25,509,801	25,509,801
b. Unsecured Loans		4,000,000	4,000,000
3. DEFERRED INCOME TAX LIABILITY			
		20,245,481	17,853,474
TOTAL		<u>248,859,781</u>	<u>246,467,775</u>
II APPLICATION OF FUNDS			
1. FIXED ASSETS			
a. Gross Block	3	153,500,917	153,500,917
Less Depreciation		40,730,014	34,058,927
b. Net Block		112,770,902	119,441,990
2. CURRENT ASSETS, LOANS & ADVANCES			
a. Inventories		598,430	598,430
b. Sundry Debtors	4	829,980	829,980
c. Cash & Bank Balance	5	405,585	251,664
d. Loans & Advances	6	24,984,919	24,984,919
Less: Current Liabilities & Provisions	7	3,093,108	3,068,108
NET CURRENT ASSETS		23,725,806	23,596,885
3. MISCELLANEOUS EXPENDITURE			
(to the extent not written off or adjusted)			154,390
4. PROFIT & LOSS ACCOUNT			
		112,363,073	103,274,510
TOTAL		<u>248,859,781</u>	<u>246,467,775</u>

NOTES TO ACCOUNTS

9

AS PER OUR REPORT OF EVEN DATE

FOR AND ON BEHALF OF THE BOARD

for **P. MURALI & CO.,**
CHARTERED ACCOUNTANTS

D.KRISHNA KUMAR RAJU
CHAIRMAN

D.SREERAMA RAJU
MANAGING DIRECTOR

P.MURALI MOHANA RAO
PARTNER

PLACE: HYDERABAD
DATE : 02-09-2005

NEOCURE THERAPEUTICS LIMITED



PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31-03-2005

PARTICULARS	SCHEDULE No.	ENDING 31-03-2005 (Rupees)	ENDING 31-03-2004 (Rupees)
1 INCOME			
Income		540,000	540,000
TOTAL		540,000	540,000
2 EXPENDITURE			
Administrative Expenses	8	411,079	382,000
Depreciation		6,671,087	4,771,053
Miscellaneous Expenses W/o		154,390	154,393
TOTAL		7,236,556	5,307,446
3 PROFIT / (LOSS) BEFORE TAX		(6,696,556)	(4,767,446)
4 PROVISION FOR TAXATION		-	-
5 DEFERRED INCOME LIABILITY FOR CURRENT YEAR		(2,392,007)	(1,581,229)
6 PROFIT / (LOSS) AFTER TAX		(9,088,563)	(6,348,675)
7 BALANCE BROUGHT FORWARD PROFIT/(LOSS)		(103,274,510)	(96,925,835)
8 BALANCE CARRIED FORWARD		(112,363,073)	(103,274,510)
EARNINGS PER SHARE		(0.56)	(0.39)
NOTES TO ACCOUNTS	9	--	--

AS PER OUR REPORT OF EVEN DATE
for P. MURALI & CO.,
CHARTERED ACCOUNTANTS

FOR AND ON BEHALF OF THE BOARD

P.MURALI MOHANA RAO
PARTNER

D.KRISHNA KUMAR RAJU
CHAIRMAN

D.SREERAMA RAJU
MANAGING DIRECTOR

PLACE: HYDERABAD
DATE : 02-09-2005

NEOCURE THERAPEUTICS LIMITED



SCHEDULE 1 SHARE CAPITAL

PARTICULARS	AS AT 31-03-2005 (Rupees)	AS AT 31-03-2004 (Rupees)
AUTHORISED		
20,000,000 Equity Shares of Rs.10/-Each	<u>200,000,000</u>	<u>200,000,000</u>
ISSUED, SUBSCRIBED & PAID-UP:		
16199100 Shares of Rs.10/-Each	<u>161,991,000</u>	<u>161,991,000</u>
	<u>161,991,000</u>	<u>161,991,000</u>

SCHEDULE 2 SECURED LOANS

PARTICULARS	AS AT 31-03-2005 (Rupees)	AS AT 31-03-2004 (Rupees)
Working Capital Borrowing From Banks	<u>25,509,801</u>	<u>25,509,801</u>
	<u>25,509,801</u>	<u>25,509,801</u>

SCHEDULE - 3 FIXED ASSETS

(S L M)

Particulars	Gross block as on 01-04-2004	Additions during the year	Gross block as at 31-03-2005	Depreciation up to 31-3-2004	Depreciation during the year	Total depreciation 31-3-2005	Net block as at 31-3-2005	Net block as at 31-3-2004
Land	89,491	—	89,491	—	—	—	89,491	89,491
Land & Buildings	44,566,121	—	44,566,121	7,635,870	1,488,508	9,124,379	35,441,742	36,930,250
Furniture & Fixtures	647,844	—	647,844	330,255	41,009	371,263	276,581	317,589
Plant & Machinery	105,172,017	—	105,172,017	24,754,632	4,995,671	29,750,303	75,421,714	80,417,385
Art work	330,526	—	330,526	147,439	15,700	163,139	167,387	183,087
Blocks	597,574	—	597,574	266,275	28,385	294,660	302,914	331,299
Cylinders	918,456	—	918,456	405,325	43,627	448,951	469,505	513,131
Vehicles	46,128	—	46,128	37,569	4,382	41,951	4,177	8,559
Misc. Fixed Assets	1,132,760	—	1,132,760	481,562	53,806	535,368	597,392	651,198
	<u>153,500,917</u>	<u>—</u>	<u>153,500,917</u>	<u>34,058,927</u>	<u>6,671,087</u>	<u>40,730,014</u>	<u>112,770,902</u>	<u>119,441,990</u>

SCHEDULE 4 SUNDRY DEBTORS

PARTICULARS	AS AT 31-03-2005 (Rupees)	AS AT 31-03-2004 (Rupees)
(Debts considered good & unsecured)		
Debts outstanding for a period exceeding six months	<u>829,980</u>	<u>829,980</u>
	<u>829,980</u>	<u>829,980</u>

NEOCURE THERAPEUTICS LIMITED**SCHEDULE 5
CASH & BANK BALANCES**

PARTICULARS	AS AT	AS AT
	31-03-2005 (Rupees)	31-03-2004 (Rupees)
Cash in hand	398,356	232,356
Balances with Banks	7,229	19,308
	<u>405,585</u>	<u>251,664</u>

**SCHEDULE 6
LOANS & ADVANCES**

PARTICULARS	AS AT	AS AT
	31-03-2005 (Rupees)	31-03-2004 (Rupees)
Advances & Others	23,805,012	23,805,012
Deposits	1,179,907	1,179,907
	<u>24,984,919</u>	<u>24,984,919</u>

**SCHEDULE 7
CURRENT LIABILITIES & PROVISIONS**

PARTICULARS	AS AT	AS AT
	31-03-2005 (Rupees)	31-03-2004 (Rupees)
Sundry Creditors	582,021	582,021
Other Liabilities	2,378,483	2,378,483
Outstanding Expenses & Provisions	132,604	107,604
	<u>3,093,108</u>	<u>3,068,108</u>

**SCHEDULE 8
MANUFACTURING ,SELLING & ADMINISTRATIVE EXPENSES**

PARTICULARS	YEAR ENDED	YEAR ENDED
	31-03-2005 (Rupees)	31-03-2004 (Rupees)
Audit Fee	25,000	25,000
Other Administrative Expenses	386,079	357,000
	<u>411,079</u>	<u>382,000</u>



SCHEDULE - 9

NOTES FORMING PART OF THE ACCOUNTS

A. SIGNIFICANT ACCOUNTING POLICIES

General :

- (i) These accounts are prepared on the historical cost basis and on the accounting principles of a going concern.
- (ii) Accounting policies not specifically referred to otherwise are consistent and in consonance with generally accepted accounting principles.

Revenue Recognition :

- (i) The Company follows the Mercantile system of Accounting and recognises income and expenditure on accrual basis.
- (ii) Revenue is not recognised on the grounds of prudence, until realised in respect of liquidated damages, delayed payments as recovery of the amounts are not certain.

Fixed Assets :

- (i) Fixed assets are stated at cost less accumulated depreciation. Cost of acquisition of fixed assets is inclusive of freight, duties, taxes and incidental expenses thereto.

Depreciation and Amortisation :

- (i) Depreciation is provided on straight line method on pro-rata basis and at the rates and manner specified in the Schedule XIV of the Companies Act, 1956.
- (ii) Preliminary Expenses are amortised over the period of 10 years.

Inventories:

Inventories are valued at cost or market price whichever is lower.

Taxation :

The current charge for income tax is calculated in accordance with the relevant tax regulations applicable to the Company. Deferred tax asset and liability is recognised for future tax consequences attributable to the timing differences that result between the profit offered for income tax and the profit as per the financial statements. Deferred tax asset & liability are measured as per the tax rates/laws that have been enacted or substantively enacted by the Balance Sheet date.

Earning Per Share:

The earning considered in ascertaining the companies earning per share comprise net profit after tax. The number of shares used in computing basic earning per share is the weighted average number of shares outstanding during the year.

Gratuity :

No provision for gratuity has been made as no employee has put in qualifying period of service for entitlement of this benefit.

NEOCURE THERAPEUTICS LIMITED



B. NOTES ON ACCOUNTS

- 1 Particulars of Employees in accordance with Sub-section (2A) of Section 217 of the Companies Act, 1956 read with Companies (Particulars of Employees) Rule 1975. NIL
- 2 Auditor's Remuneration :

	<u>Current Year</u>	<u>Previous Year</u>
	<u>(Rs.)</u>	<u>(Rs.)</u>
Audit Fee	25,000/-	25,000/-
- 3 Detailed information regarding quantitative particulars under part II of Schedule VI to the Companies Act, 1956.

<u>Quantitative Particulars</u>	<u>Qty.</u>	<u>Value</u>
A. Turnover	Nil	
B. Purchases	Nil	
C. Opening Stock		
Raw Materials (Kgs.)	2506.780 kgs	580501.00
Medicines (Bottles)	900 Nos.	12679.00
Medicines (Boxes)	98 Nos.	5250.00
d. Closing Stock		
Raw Materials (Kgs.)	2506.78 kgs	580501.00
Medicines (Bottles)	900 Nos.	12679.00
Medicines (Boxes)	98 Nos.	5250.00
- 4 There are no dues to SSI Units outstanding for more than 30 days.
- 5 No confirmations were obtained from debtors/creditors as to the balances receivable from/ payable to them as at year end.
- 6 As there is no timing difference of depreciation during the year, deferred income tax Asset/ Liability for the current year not provided in accordance with Accounting Standard 22 (AS 22) issued by the ICAI. (Previous year Rs.1581229/- towards deferred income tax Liability).
- 7 Previous years figures have been regrouped wherever necessary.
- 8 The figures have been rounded off to the nearest rupee.

SIGNATURES TO SCHEDULES 1 To 9

As per our report of even date
For **P.MURALI & CO.,**
CHARTERED ACCOUNTANTS

For and on behalf of the Board
NEOCURE THERAPEUTICS LIMITED

P.MURALI MOHANA RAO
PARTNER

D.KRISHNA KUMAR RAJU
CHAIRMAN

D.SREERAMA RAJU
MANAGING DIRECTOR

PLACE : HYDERABAD
DATE : 02-09-2005

NEOCURE THERAPEUTICS LIMITED



CASH FLOW STATEMENT FOR THE YEAR ENDED 31-03-2005

	31-3-2005 (Rs. In lakhs)	31-3-2004 (Rs. In lakhs)
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Net Profit/ (Loss) before taxation, and extraordinary items	(66.97)	(47.67)
Adjustments for:		
Depreciation	66.71	47.71
W/o expenses	1.54	1.54
Interest expenses	-	-
Operating Profit before working capital changes	1.28	1.58
Trade and other receivables	-	-
Inventories	-	-
Trade payables	0.25	0.25
Cash generated from operations	1.53	1.83
Interest paid	0.00	0.00
Direct Taxes paid	-	-
Cash flow before extraordinary items	-	-
Extraordinary items	-	-
NET CASH FLOW OPERATING ACTIVITIES	1.53	1.83
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	-	-
Decrease in capital work in progress	-	-
NET CASH USED IN INVESTING ACTIVITIES	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES:		
Proceeds from Equity	-	-
Proceeds from Share premium	-	-
Net Proceeds from Long Term Borrowings	-	-
NET CASH USED IN FINANCING ACTIVITIES	-	-
Net increase in cash and cash equivalents	1.53	1.83
Cash and Cash equivalents (Opening Balance)	2.52	0.69
Cash and Cash equivalents (Closing Balance)	4.05	2.52

FOR AND ON BEHALF OF THE BOARD

D.KRISHNA KUMAR RAJU
Chairman

D.SREE RAMA RAJU
Managing Director

Place : Hyderabad
Date : 02-09-2005

CERTIFICATE

To
The Board of Directors
M/s Neocure Therapeutics Limited

We have examined the attached Cash Flow Statement of M/s Neocure Therapeutics Limited for the year ended 31st March, 2005. The Statement has been prepared by the company in accordance with the requirement of Clause 32 of listing agreement with Stock Exchange and is based on and agreement with the corresponding Profit & Loss Account and Balance Sheet of of the Company covered by our report of 02-09-2005 to the members of the company.

for **P. MURALI & CO.,**
CHARTERED ACCOUNTANTS

Place: Hyderabad.
Date : 02-09-2005

(P. MURALI MOHANA RAO)
PARTNER

NEOCURE THERAPEUTICS LIMITED



STATEMENT PURSUANT TO PART IV OF SCHEDULE VI TO THE COMPANIES ACT, 1956

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

I. REGISTRATION DETAILS

Registration No. - State Code

Balance Sheet

Date Date Month Year

II. CAPITAL RAISED DURING THE YEAR (AMOUNT IN Rs. THOUSANDS)

PUBLIC ISSUE	RIGHTS ISSUE
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>
BONUS ISSUE	PRIVATE PLACEMENT
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>

III. POSITION OF MOBILISATION AND DEPLOYMENT OF FUNDS (AMOUNT IN RS. THOUSANDS)

TOTAL LIABILITIES	TOTAL ASSETS
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="2"/> <input type="text" value="4"/> <input type="text" value="8"/> <input type="text" value="8"/> <input type="text" value="6"/> <input type="text" value="0"/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="2"/> <input type="text" value="4"/> <input type="text" value="8"/> <input type="text" value="8"/> <input type="text" value="6"/> <input type="text" value="0"/>

SOURCES OF FUNDS

PAID - UP CAPITAL	RESERVES & SURPLUS
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="1"/> <input type="text" value="6"/> <input type="text" value="1"/> <input type="text" value="9"/> <input type="text" value="9"/> <input type="text" value="1"/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="3"/> <input type="text" value="7"/> <input type="text" value="1"/> <input type="text" value="1"/> <input type="text" value="3"/>
SECURED LOANS	UNSECURED LOANS
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="2"/> <input type="text" value="5"/> <input type="text" value="5"/> <input type="text" value="1"/> <input type="text" value="0"/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="4"/> <input type="text" value="0"/> <input type="text" value="0"/> <input type="text" value="0"/>
	DEFERRED TAX
	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="2"/> <input type="text" value="0"/> <input type="text" value="2"/> <input type="text" value="4"/> <input type="text" value="5"/>

APPLICATION OF FUNDS

NET FIXED ASSETS	INVESTMENTS
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="1"/> <input type="text" value="1"/> <input type="text" value="2"/> <input type="text" value="7"/> <input type="text" value="7"/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>
NET CURRENT ASSETS	MISC. EXPENDITURE
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="2"/> <input type="text" value="3"/> <input type="text" value="7"/> <input type="text" value="2"/> <input type="text" value="6"/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>
ACCUMULATED LOSSES	
<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="1"/> <input type="text" value="1"/> <input type="text" value="2"/> <input type="text" value="3"/> <input type="text" value="6"/> <input type="text" value="3"/>	

* Net Fixed Assets includes capital work-in-progress.

IV. PERFORMANCE OF COMPANY (AMOUNT IN Rs. THOUSANDS)

	TURNOVER		TOTAL EXPENDITURE
	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="5"/> <input type="text" value="4"/> <input type="text" value="0"/>		<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="7"/> <input type="text" value="2"/> <input type="text" value="3"/> <input type="text" value="7"/>
+ -	PROFIT/ LOSS BEFORE TAX	+ -	PROFIT/ LOSS AFTER TAX
<input type="text" value=""/> <input type="text" value=""/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="6"/> <input type="text" value="6"/> <input type="text" value="9"/> <input type="text" value="7"/>	<input type="text" value=""/> <input type="text" value=""/>	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="6"/> <input type="text" value="6"/> <input type="text" value="9"/> <input type="text" value="7"/>
	EARNING PER SHARE IN Rs.		DIVIDEND RATE %
	<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="0"/> <input type="text" value="5"/> <input type="text" value="6"/>		<input type="text" value=""/> <input type="text" value=""/> <input type="text" value="N"/> <input type="text" value="I"/> <input type="text" value="L"/> <input type="text" value=""/>

V. GENERIC NAMES OF THREE PRINCIPAL PRODUCTS / SERVICES OF COMPANY

Item Code No. (ITC Code)

PRODUCT

DESCRIPTIONS

PRINTED MATTER

BOOK POST

If undelivered please return to :

NEOCURE THERAPEUTICS LIMITED

G-4/B, SEIE, Kattedan, Hyderabad - 500 077.